Off-Label Use of Inhaled Nitric Oxide After Release of NIH Consensus Statement

Abstract

The rates of off-label iNO use in preterm infants continue to rise despite evidence revealing no clear benefit in this population. This pattern of iNO prescription is not benign and comes with economic consequences.